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Chronic inﬂammation is a key feature of insulin resistance and obesity. Toll-Like Receptor 4 (TLR4), involved in modulating
innate immunity, is an important mediator of insulin resistance and its comorbidities. TLR4 contributes to the development of
insulin resistance and inﬂammation through its activation by elevated exogenous ligands (e.g., dietary fatty acids and enteric
lipopolysaccharide) and endogenous ligands (e.g., free fatty acids) which are elevated in obese states. TLR4, expressed in insulin
target tissues, activates proinﬂammatory kinases JNK, IKK, and p38 that impair insulin signal transduction directly through
inhibitory phosphorylation of insulin receptor substrate (IRS) on serine residues. TLR4 activation also leads to increased
transcription of pro-inﬂammatory genes, resulting in elevation of cytokine, chemokine, reactive oxygen species, and eicosanoid
levels that promote further insulin-desensitization within the target cell itself and in other cells via paracrine and systemic eﬀects.
Increased understanding of cell type-speciﬁc TLR4-mediated eﬀects on insulin action present the opportunity and challenge of
developing related therapeutic approaches for improving insulin sensitivity while preserving innate immunity.
1.Introduction
1.1. Insulin Resistance. Insulin resistance is a primary defect
leading to and a characteristic feature of type 2 diabetes
[1,2].Thestateofinsulinresistanceleadstoincreasedinsulin
secretion by pancreatic β-cells and compensatory hyper-
insulinemia. As long as compensatory hyperinsulinemia is
suﬃcient to overcome the insulin resistance, fasting glycemia
and glucose tolerance remain relatively normal. In patients
destined to develop type 2 diabetes, β-cell compensation
eﬃciency declines and relative insulin insuﬃciency develops
leading to impaired glucose tolerance and eventually frank
type 2 diabetes. Although there is still some debate as to
whether the insulin resistance or the β-cell defect comes ﬁrst,
most epidemiologic studies indicate that in the early, pre-
diabetic state, insulin resistance is the initiating abnormality.
Type 2 diabetes only develops in insulin resistant patients
with a concomitant β-cell defect. As such, many subject
groups with insulin resistance who do not have diabetes.
These include patients with simple obesity, polycystic ovar-
i a ns y n d r o m e ,a n da d v a n c e da g e .T h e r ea r ean u m b e ro f
other abnormalities associated with insulin resistance that
are included in the state of metabolic syndrome. Patients
with metabolic syndrome are insulin resistant, hyperin-
sulinemic, and dyslipidemic (usually elevated triglyceride
and decreased HDL levels) and frequently also have hyper-
tension, nonalcoholic fatty liver disease, albuminuria, and
increased plasminogen activator inhibitor 1 (PAI-1) levels.
Epidemiologic evidence demonstrates that patients with
metabolic syndrome have a high likelihood of developing
type 2 diabetes and cardiovascular disease. Thus, while it
is well established that treatment of insulin resistance has
beneﬁcial eﬀects in patients with type 2 diabetes, it is
becoming increasingly clear that enhanced insulin sensitivity
is also therapeutically important in nondiabetic individuals
with insulin resistance.
1.2. TLR4 Activity and Insulin Resistance-Associated Inﬂam-
mation. Activation of the pro-inﬂammatory pathway has
been described in a variety of insulin resistant states [3–6].
Chronic inﬂammation inhibits insulin sensitivity through2 Gastroenterology Research and Practice
the activation of signaling pathways that directly interfere
with the normal function of key components of the insulin
signaling pathway [5, 6]. Inﬂammation impairs insulin
sensitivity in part via the activation of the Toll-Like Receptor
(TLR) family of pattern recognition receptors, speciﬁcally
TLR2 and TLR4. For the purposes of this review, we will
focus on the role of TLR4 in insulin resistance. TLR4 is a
cell surface receptor that generates innate immune responses
to pathogens by inducing signaling cascades of kinase and
transcription factor activation (Figure 1). These cascades
lead to the generation of pro-inﬂammatory cytokines,
chemokines, eicosanoids, and reactive oxygen species (ROS),
all eﬀectors of innate immunity. Notably, TLR4 is expressed
in many cell components of insulin target tissues, including
liver, adipose tissue, skeletal muscle, vasculature, pancreatic
β cells, and brain (Figure 2). Thus, activation of TLR4
can dampen insulin action directly, through activation of
pro-inﬂammatory kinases and ROS, and indirectly, via
activation of cytokine signaling cascades and systemic
release of pro-inﬂammatory, insulin-desensitizing factors
(Figure 1).
Lipopolysaccharide (LPS) and its endotoxic moiety Lipid
A are potent agonists of TLR4. LPS is an outer membrane
component of gram-negative bacteria and is composed of
oligosaccharides and acylated saturated fatty acids (SFA).
Free SFA are also reported to bind and activate TLR4.
However, there are conﬂicting interpretations of these data
which are discussed in more detail below. Endogenous
activators of TLR4 include S100A8/S100A9 (calprotectin)
[7], high-mobility group 1 (HMBG1) [8], ﬁbronectin [9],
and minimally modiﬁed low-density lipoprotein (mmLDL)
[10]. LPS binding protein (LBP), CD14 and MD-2 serve as
TLR4 accessory proteins that facilitate ligand delivery in the
circulation and receptor binding. Two signaling pathways are
initiated by TLR4 activation (Figure 1). One, modulated by
MyD88 and TIRAP, activates IKK, p38, JNK, CREB, AP2,
and NFκB and leads to the induction of pro-inﬂammatory
genes. The other pathway, modulated by TRAM and TRIF,
requires internalization of TLR4 (not depicted in Figure 1),
activates IKK, NFκB, and IRF3, and leads to induction of
type 1 interferon genes. Transcriptional activation by these
pathways induces robust expression of thousands of genes,
depending on the cell type, that propagate the defense
mechanisms of innate immunity. These signaling cascades
induce feed forward signaling cascades (e.g., via IL-6 and
TNFα receptor activation) and negative feedback loops
(e.g., via transcriptional activation of the IκBg e n e )[ 3]. In
addition, TLR4-activated pathways inhibit the components
of other signaling systems, for example, insulin signaling via
IRS1 serine phosphorylation (Figure 1).
1.3. Regulation of TLR4. TLR4 expression and signaling
are regulated by a variety of inputs, explained brieﬂy
here. Adiponectin impairs LPS activation of TLR4 signal-
ing pathways in hepatic Kupﬀer cells and macrophages
through mechanisms involving AMPK, IL-10, and heme
oxygenase-1 [11–15]. AMPK also impairs LPS-induced IκB
degradationandCREBactivationinmacrophages[16].Acti-
vated nuclear receptor transcription factors glucocorticoid
receptor (GR), peroxisome proliferators-activated receptor
gamma (PPARγ), and liver X receptor alpha (LXRα)e a c h
transrepress TLR4-activated gene transcription and impair
TLR4-mediated inﬂammation [17]. PPARγ activation also
inhibits expression of TLR4 [18, 19] and, conversely, TLR4
activation inhibits expression of PPARγ [20]. Sex hormones
can also aﬀect TLR4 expression. Progesterone impairs
LPS/TLR4 signaling eﬃcacy via GR and progesterone recep-
tor [21, 22]. Estrogen treatment of ovariectomized mice
increases cell surface localization of TLR4 but does not
change total cellular protein levels [23]. Testosterone down-
regulates TLR4 expression in macrophages both in vitro and
invivo[24].Long-chainpolyunsaturatedomega-3fattyacids
(ω-3 FA) including DHA and EPA are antagonists of TLR4
acti vationb yLPSandSF Ainh umansandmic e[25–27].One
mechanism by which ω-3 FA interfere with TLR4 signaling
is by altering plasma membrane lipid raft composition and
function. For example, ω-3 FA block the ability of LPS and
SFA treatments to stimulate assembly of TLR4 homodimers
and signaling component complexes within lipid rafts,
preventing subsequent signal transduction [28]. Stearoyl
CoA desaturase 1 (SCD1) deﬁcient mice, although protected
from high-fat diet-induced insulin resistance, accumulate
macrophage plasma membrane SFA, exhibit greater suscep-
tibility to atherosclerosis, and are hypersensitive to inﬂam-
matory stimuli including those signaling through TLR4
[29, 30]. Supplementation with ω-3 FA completely protects
SCD1 deﬁcient mice from diet-induced atherosclerosis and
metabolic syndrome [31]. These SCD1 deﬁcient phenotypes
may, in part, relate to lipid raft compositional changes
that alter TLR4 signaling eﬃciency. SFA are conducive to
formation and function of lipid rafts, essential sites of
particular signal transduction pathways including TLR4, but
lipid raft function and signaling component assembly are
disrupted by ω-3 FA [32–34].
1.4. Role of Saturated Fatty Acids and Gut-Generated LPS as
TLR4 Ligands. Are saturated fatty acids actual ligands of
TLR4? SFA activation of TLR4 is an attractive link between
obesity, insulin resistance, and inﬂammation, as cellular
exposure to SFA greatly increases in the obese state. SFA are
acyl components of LPS, activate TLR4 in vitro, and bind
directly to TLR4/MD2/LPS crystal structures, although in an
orientation that would probably rely on their presentation
in an acylated form [35, 36]. Recent studies document
endotoxin contamination of experimental reagents (such as
bovine serum albumin, BSA) which would generate false-
positive experimental results regarding the TLR4 agonistic
eﬀects of SFA [37–39]. LPS contamination is pervasive and
LPS levels can only be assayed indirectly [31, 40]. Nonethe-
less,manypublicationsdocumentactivationofTLR4viaSFA
and many of these include samples that control for possible
endotoxin contamination, for example, studies wherein
BSA-complexed SFA treatments activate TLR4 eﬀects but
BSA alone and BSA-complexed monounsaturated fatty acid
treatments do not. Extensive literature suggests that high-
fat diet-augmented postprandial endotoxemia is a possible
mode by which dietary SFAs induce inﬂammation through
TLR4 in diet-induced obesity (DIO) models.Gastroenterology Research and Practice 3
IKKγ
BTK
Nucleus IRF3 CREB
TLR4
NFκB
NFκB IκB
MD2
AP-1
LPS + other ligands
LBP
MyD88
TIRAP
TRAM
TRIF
TRAF3
IKKε
TBK1
IRF3
IL-6
TNFα
IL-6R
TNFαR
IRAK1, 2, 4
TRAF6
MEKK1
TAK1
TAB1, 2 IKKα,β
MKK3/6
p38
JNK
∗
∗
∗
∗
∗
STAT3
InsulinR
Insulin
IRS
PI3K
Akt
Glucose uptake
FA synthesis
Glycogen synthesis
transcription
Ser-P
MKK4/7
Systemic insulin
resistance
Extracellular
Intracellular
C
D
1
4
S
O
C
S
3
Involved in inhibitory
IRS serine phosphorylation
PKC
∗
∗
↑ Transcription of pro-inﬂammatory regulators
e.g., IL-6, TNFα, iNOS, COX2, IL-1, IL-12, MCP1, INFβ and γ
↑ ROS∗
Figure 1: Schematic of TLR4 signaling cascades. Activation of TLR4 signal transduction through MyD88/TIRAP and TRAM/TRIFpathways
leads to activation of innate immune responses and inhibition of insulin signal transduction, primarily through IRS serine phosphorylation.
Additional cellular responses to TLR4 activation not shown include activation of NADPH oxidase, cytoskeletal rearrangement, and
internalization of TLR4 complexes to endosomal compartments.
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Figure 2: Distribution of TLR4 expression in the integrated organ/tissue systems that modulate energy homeostasis and insulin sensitivity.
Schematic representation of the cross-talk between tissues. Adipose tissue shown in the macrophage-enriched, inﬂamed state.4 Gastroenterology Research and Practice
Both high-fat diets and high-fructose diets inﬂuence
enterobacterial bacterial production and circulating levels of
LPS/endotoxin by altering gut ﬂora growth and composi-
tion and gut permeability [41–44]. Dietary lipids facilitate
LPS incorporation into chylomicrons [45] and TLR4 is
responsibleforphagocytosisofgram-negativebacteriabygut
enterocytes [46], each contributing to postprandial endo-
toxemia. Insulin resistant DIO and genetically obese mice
and type 2 diabetic humans [41, 46–48] all exhibit elevated
plasma LPS levels and endotoxemia is correlated with insulin
resistance and atherogenic markers. Thus, chronic elevation
ofcirculatinggut-generatedLPSor“metabolicendotoxemia”
[49] would result in sustained, systemic pro-inﬂammatory
stimulation of TLR4. Interestingly, germ-free mice or mice
treated with antibiotics speciﬁc for gram-negative bacteria
do not acquire high-fat diet-induced insulin resistance or
other associated metabolic abnormalities [50–52]. Geneti-
cally obese ob/ob mice treated with an LPS inhibitor or in
a CD14 KO background have reduced inﬂammation and
metabolic abnormalities compared to normal ob/ob mice
[51, 52] which suggests that these ob/ob phenotypes are
partly mediated by gut LPS and TLR4 signaling.
1.5. Mouse Model Overview. Several mouse model stud-
ies have demonstrated the importance of TLR4 and its
signaling components in diet-induced insulin resistance,
inﬂammation, and atherosclerosis. These studies include
thoseconductedinwholebodyTLR4knockout(KO)orloss-
of-function mutations [26, 53–55], hematopoetic TLR4 KO
[56], and whole body KOs of MyD88 [57]o rC D 1 4[ 58, 59].
Some discrepancies in phenotypic reports with regard to
food intake, weight gain, and adipose tissue macrophage
accumulation will be discussed in the sections below. There
are two nonsynonymous polymorphisms (SNPs) in the
human TLR4 gene that result in changes in the TLR4
extracellular domain. These polymorphisms are reported to
alter responsiveness to TLR4 activation and correlate with
protection from atherosclerosis, CVD and the metabolic
syndrome in some populations [60–62].
In the next sections, we will highlight tissue-speciﬁc
eﬀects of TLR4 activation and its role in insulin resistance.
As many of the mouse models are whole body KOs of
TLR4 signaling, it is unclear which exact cell type(s) mediate
the phenotypes observed in these models. TLR4 expression
in tissues, the mediate glucose homeostasis, and insulin
sensitivity is shown in Figure 2 along with a schematic
representation of the intra- and intertissue crosstalk that
exists in vivo.
1.6. Adipose Tissue. Adipose tissue acts not only as a storage
depot for excess calories, but also secretes large numbers of
hormones, cytokines, and chemokines that inﬂuence energy
homeostasis and metabolism (Figure 2). Adipose tissue con-
sists of a variety of cell types, including adipocytes, immune
cells (macrophages and lymphocytes), preadipocytes, and
endothelial cells. Among these cell types, adipocytes and
macrophages release cytokines and chemokines such as
MCP-1, IL-1β,I L - 6 ,a n dT N F - α [5] that promote inﬂam-
mation. In addition, adipocytes are the unique source of
hormones termed “adipokines” such as leptin [63, 64]a n d
adiponectin [65], which can promote insulin sensitivity as
well as resistin and retinol-binding protein 4 (RBP4), which
can impair insulin sensitivity [6].
In states of chronic nutrient excess and obesity, insulin
resistance manifests through several mechanisms such as
increased free fatty acid (FFA) ﬂux, ER stress, and micro-
hypoxia in adipocytes, all of which are associated with
increased inﬂammation [6]. In recent years, much interest
hasbeenfocusedonthisassociationbetweenobesity,chronic
inﬂammation and insulin resistance. In 2003, two land-
mark studies showed bone-marrow derived macrophages
invade adipose tissue in obese states [66, 67]. Recruited
macrophages may initially remove dying cells and contribute
toadiposetissuevascularization,buttheiractivationtowards
aninﬂammatoryphenotypesoonresultsincytokineproduc-
tion [68]. These macrophages contribute to the development
of inﬂammation in adipose tissue and are believed to be a
key contributor to insulin resistance [69]. This relationship
between increased macrophage inﬁltrates and obesity has
since been veriﬁed in human studies [70]. A growing body
of literature is focused on the role of these adipose tissue
macrophages (ATMs) in insulin resistance, characterizing
their activation, recruitment, and function.
Attenuating the inﬂammatory signaling pathway by gene
knockout experiments has been shown to reduce obesity-
related insulin resistance in mice [69, 71–74]. For example,
mice with myeloid cell-speciﬁc deletion of IKKβ or JNK1
have signiﬁcantly improved glucose tolerance and insulin
sensitivity despite high-fat diet-induced obesity. Several lines
of evidence point to the involvement of TLR signaling in this
paradigm. For example, TLR4 expression is highly abundant
in pro-inﬂammatory macrophages [75, 76] and diﬀeren-
tiated adipocytes [77, 78]. Moreover, TLR4 expression in
adipocytes increases with obesity [26] and it can be activated
by LPS to induce NFκB activation and cytokine production
in both rodent and human tissues [79–81]. SFA acylated
in the lipid A moiety of LPS is essential for the biological
activity of LPS [82]. LPS and SFA have also been shown
to attenuate insulin signaling in adipocytes with decreased
phosphorylation of Akt and GSK3β [78].
Most intriguingly, TLRs in adipocytes [26, 83]a n dp r o -
inﬂammatory macrophages [76] may be directly activated
by nutrients, particularly SFA. Although it is not yet clear
if LPS contamination may contribute to any of these
ﬁndings, dietary SFA appear to diﬀerentially modify the
risk of developing many chronic inﬂammatory diseases in
both human and animal studies [84]. In contrast, ﬁsh oil-
derived ω-3 FA can mitigate the eﬀect of LPS and free SFA-
induced inﬂammation in macrophages [25] and adipocytes
[26] and prevent high-fat diet-induced insulin resistance
in rodents [85]. Taken together, this evidence suggests that
elevated FFAs in obesity activate TLR signaling and impair
insulin action, providing yet another link between obesity,
inﬂammation, and insulin resistance.
Toll-like receptors in adipose tissue play a key role in
initiating the inﬂammatory response, thereby promoting
insulin resistance. Several studies to date have shown that
disruption of the TLR4 gene in mice confers protectionGastroenterology Research and Practice 5
from obesity-induced inﬂammation and insulin resistance
[26, 54, 86–88]. Several models of TLR4 deﬁciency have
been studied in this context. Two LPS-resistant naturally
occurring mouse strains have been identiﬁed with loss-of-
function (C3H/HeJ mice) or deletion (C57BL/10ScN mice)
mutations in the TLR4 gene [55, 81]. TLR4 null mice have
also been generated using homologous recombination [80].
Body composition diﬀers between mouse strains following
high-fat feeding, with unaltered [88] or decreased [55,
86, 87] weight in C3H/HeJ and C57BL/10ScN mice, and
unaltered or increased weight in TLR4−/− mice [26]. It is
unknown whether this divergence results from diﬀerences in
TLR4 mutations, mouse strains, or other factors. However,
in both models, TLR4 signaling in macrophages and adipose
tissue appears to regulate whole body glucose homeostasis
via eﬀects on adipose, muscle, and liver tissues.
Since body composition strongly inﬂuences insulin sen-
sitivity, it is challenging to ascertain whether improved
glucose metabolism results from altered TLR4 expression or
decreased body weight. Therefore, models in which body
weight is unaltered or increased are advantageous. There are
two papers published to date showing increased adiposity
following high-fat feeding in mice with disrupted TLR4 gene
expression [26, 88]. In these studies, adipose inﬂammation
was greatly attenuated with reduced expression of pro-
inﬂammatory genes, despite their greater adiposity. TLR4
deletion also improved insulin sensitivity, with higher rates
of glucose disposal into skeletal muscle and adipose tissue,
and reduced inﬂammation and insulin resistance induced
by either LPS or FFAs in isolated primary adipocytes [26,
88]. Moreover, while in vivo lipid infusion promotes insulin
resistance and NFκB activation in adipose tissue of control
mice, similar eﬀects were not observed in TLR4 knockout
mice [26].
Additional work indicates that TLR4-mediated alter-
ations in macrophage activity underlie the adipose-speciﬁc
improvements in inﬂammation and insulin. Saturated fatty
acids such as palmitate, lauric acid, and oleate fail to elicit
TNFα production or IKKβ degradation in elicited peritoneal
macrophages from TLR4 mutant mice [26, 89]. Further-
more, mice with myeloid-speciﬁc ablation of TLR4, gener-
ated by transplanting bone marrow from TLR4−/− animals
into wild-type mice, demonstrate signiﬁcantly improved
insulin sensitivity in adipose tissue with reduced ATMs and
adipose pro-inﬂammatory gene expression [54]. Because
these chimeric mice possess TLR4 deﬁciency only in bone
marrow-derived cells, it is possible to determine the contri-
bution of hematopoietic TLR4 to insulin sensitivity. In addi-
tion, body weight and adipose depot sizes are equal between
chimeric and control mice, such that diﬀerences in adiposity
are not a confounding factor in the comparison between
groups. Similar conclusions were drawn from studies in
mice lacking the TLR4/TLR2 coreceptor CD14. Adipose
tissue from obese CD14 null mice had fewer macrophages,
with reduced glucose intolerance despite increased body
weight [59]. Interestingly, TLR4 expression in peripheral
bloodmononuclearcellsisreducedinoverweightindividuals
with metabolic syndrome that undergo weight loss [90].
Although our understanding of macrophage function is
incomplete, it appears that their absence in adipose tissue
confers protection against insulin resistance during nutrient
overload.
1.7. Liver. The liver is comprised of heterogeneous cell types
including hepatocytes, stellate cells, endothelial cells, and
immune cells. Liver-resident macrophages called Kupﬀer
cells make up 10% of cells in the liver and 80%–90% of all
tissue macrophages in the body [91]. They are localized at
sinusoids where they are in close contact with circulating
factors (hormones, cytokines, lipids, danger signals, post-
prandial LPS, etc.). Kupﬀer cells, able to migrate and cross-
talk with other cell types within the liver, are important
mediators of liver inﬂammation and non-alcoholic fatty
liver disease (NAFLD), reviewed in more detail within this
volume [92]. TLR4 is expressed on Kupﬀer cells and other
liver cell components and modulates liver pro-inﬂammatory
activity induced by high-fat diet- and fructose-induced
hepatic steatosis and insulin resistance in mouse models
[26, 44, 54, 93], although a direct role for liver tissue
TLR4 in these processes is unclear. In obese patients with
nonalcoholic steatohepatitis (NASH), liver tissue levels of
activated pro-inﬂammatory NFκB and AP-1 were correlated
with oxidative stress and insulin resistance [94]. Both whole
body and myeloid-speciﬁc TLR4 signaling deﬁciency result
in reduced lipid accumulation, inﬂammation, JNK and IRS1
serine phosphorylation, and insulin resistance in liver [26,
54, 59, 86–88]. Interestingly, acute LPS treatment inhibits
hepatic glucose production in vivo and in vitro via a
TLR4 signaling pathway and induces insulin resistance 48
hours post-treatment in vivo, suggesting possible cross-talk
betweenTLR4andinsulinreceptorsignalingpathwaysinthis
system [95]. The hypoglycemic eﬀects of acute LPS are PI3K-
and TNFα-independent and additive when combined with
insulin. There are several models of how steatosis could facil-
itate activation of TLR4 in Kupﬀer cells [93]. Increased lipid
content and exposure can aﬀect TLR4 signaling complex
assembly, endosomal sorting, and signaling cascade ﬂow by
altering lipid raft composition and membrane ﬂuidity. Liver
hypertrophyandelevatedlipidcontentcanimpairsinusoidal
perfusion eﬃcacy and constrict circulatory ﬂow. Circulating
leukocytes, stuck within the sinusoids, would be more likely
to activate liver resident cells, including Kupﬀer cells. Liver
tissue inﬁltration of circulating monocytes might also be
facilitated in the inﬂamed, hypertrophic, and steatotic state.
In the insulin resistant state, liver-expressed TLR4 would
be exposed to elevated circulating ligands including adipose
tissue FFA and, in obese/high-fat diet states, LPS and dietary
SFA.
1.8. Muscle. Skeletal muscle is the primary site for insulin-
stimulated glucose utilization, accounting for over 75% of
this process under normal physiological conditions [96,
97]. Glucose disposal into muscle is markedly reduced
in obese, hyperinsulinemic subjects [98], underscoring the
importanceofskeletalmuscleinnormalglucosehomeostasis
and in the development of insulin resistance. Putative mech-
anisms of insulin resistance in skeletal muscle include direct
eﬀects of intramyocellular FFA metabolites, paracrine eﬀects6 Gastroenterology Research and Practice
of adipocytes, and macrophages (interspersed between mus-
cle ﬁber bundles) in muscle tissue as well as endocrine
eﬀects from adipocytes and macrophages present in adipose
tissue. As an example of the latter, the production of the
pro-inﬂammatory cytokine TNFα from adipose tissue can
impair insulin signaling in muscle through inhibitory serine
phosphorylation of IRS-1 [99].
TLR4 has been shown to regulate substrate metabolism
in muscle, favoring glucose oxidation rather than fatty
acid oxidation in the absence of insulin [100]. Emerging
data indicates that TLR signaling may also underlie the
development of chronic inﬂammation and insulin resistance
in skeletal muscle. Skeletal muscle cells and intact whole
muscle express multiple TLRs, including TLR2 and TLR4
[101], that are responsive to LPS [102]. Moreover, skeletal
muscle TLR4 gene and protein expression are signiﬁcantly
elevated in muscle from obese subjects with type 2 diabetes
[103]. In these individuals, TLR4 protein expression in
musclecorrelateswiththeseverityofinsulinresistance.TLR4
contributes to skeletal muscle metabolism. Activation of
TLR4 has also been shown to regulate substrate utilization
in muscle, favoring glucose oxidation rather than fatty acid
oxidation in the basal state.
Much of the current data implicates saturated FFAs
as ligands for TLRs in muscle tissue. For example, in
human myotubes and in muscle from lean human subjects,
acute palmitate treatment induces robust NFκB-activation
via TLR4 [103]. In C2C12 mouse myotubes, palmitate has
been also shown to activate NFκB, as well as JNK1/2 and
novel PKC pro-inﬂammatory pathways via TLR2 [104].
Rodent studies also show that disrupted expression of
TLR4 protects against saturated fatty acid-induced insulin
resistanceinmuscleresultinginimprovedinsulin-stimulated
glucose uptake, improved IRS1 tyrosine phosphorylation,
reduced IRS1 serine phosphorylation, and decreased JNK1
phosphorylation in TLR mutant mice [26, 87]. More recent
work indicates that conditioned media from macrophages
treated with palmitate, but not LPS, can impair glucose
uptake in muscle cells, suggesting that saturated fatty acids
mediate their eﬀects on muscle via macrophage cells [68].
1.9. Other Tissues
1.9.1. Brain. In recent years, much interest has been focused
on the role of the brain in regulating glucose metabolism.
Several investigators have identiﬁed the hypothalamus and
mesolimbic area as important sites in the regulation of food
intake, energy expenditure, peripheral insulin resistance, and
pancreatic β-cell function. For example, neural inﬂuences
on the liver and muscle directly inﬂuence glucose output
and uptake in these tissues [105]. Inﬂammatory signaling
pathways in adipose tissue have been shown to regulate
energy balance by increasing thermogenesis [106]. Studies
in TLR4 mutant mice suggest that TLR signaling in the
CNS may also contribute to obesity phenotypes by aﬀecting
nutrientintake.Forexample,TLR4nullfemalesdemonstrate
increased adiposity secondary to increased food intake on
both normal chow and high-fat diets [26]. In addition,
a study of C3H/HeJ mice showed decreased food intake
when fed ad libitum, and developed obesity when pair-
fed with control mice [88]. It is diﬃcult to ascertain
direct eﬀects of TLR signaling in the brain since TLR4
expression is disrupted in the whole body in both models.
However, high-fat diet has been shown to increase JNK1 and
NFκB activation in the hypothalamus with impaired insulin
signaling and apoptosis that may result in dysregulated
feeding control [107]. TLR4 in the hypothalamus may
activate pro-inﬂammatory pathways that contribute to the
development of insulin and leptin resistance. For example,
mice deﬁcient for the TLR adaptor molecule MyD88 in
the CNS are protected from hypothalamic inﬂammation
and leptin resistance induced by acute central application
o fp a l m i t a t ea sw e l la sf r o mi m p a i r m e n to fp e r i p h e r a l
glucose metabolism induced by either centrally administered
palmitate or by HFD [108]. However, the role of TLR4 is
still unclear as some work suggests that TLR4 may in fact
play dual roles in the hypothalamus by both activating pro-
inﬂammatory pathways and restraining apoptosis [109].
1.9.2. Pancreatic Islet. Several TLRs (TLR2, 3 and 4) are
highly expressed in human and rodent islets [110]. Although
types 1 and 2 diabetes diﬀer in etiology, β-cell destruction
eventually occurs in both cases, leading to clinical manifesta-
tions of absolute or relative insulin deﬁciency. Islet inﬂam-
mation is a well-established observation in autoimmune-
mediated type 1 diabetes. However, it has been more
recently described in type 2 diabetes and is thought to be
secondarytotoxicityinducedbyhighglucose,FFAs,cytokine
signaling, or ER stress. TLR signaling in β-cells has been
primarily implicated in autoimmune type 1 diabetes [111–
114]. Nevertheless, recent studies also implicate TLR2/4
and MyD88 in insuﬃcient β-cell compensation in type 2
diabetes. For example, the chemokine CXCL10 is highly
expressed in islets isolated from individuals with type 2
diabetes and has been shown to impair insulin secretion
and promote β-cell apoptosis via TLR4 [115]. In addition,
TLR activation by FFAs can induce the expression of
proinﬂammatory cytokines in puriﬁed mouse and human
islets [116], suggesting that the dyslipidemia associated with
insulin resistance promotes islet inﬂammation.
1.9.3. Artery and Endothelial Cells. TLR4 activity impairs
endothelial cell function and contributes to atherosclerosis.
TLR4 is required for LPS-stimulated NFκBa c t i v a t i o ni n
endothelial cells [117]. Kim et al. report that mice with
whole body deletion of TLR4 were protected against high-fat
diet-induced vascular inﬂammation (aorta) in vivo [53]. The
mice were also protected from high-fat diet-induced insulin
resistance while exhibiting the same body weight, adiposity,
and plasma insulin and FFA levels as wild-type controls.
These authors also demonstrated that the SFA palmitate
stimulated TLR4-dependent IKK and NFκB activation and
impairment of insulin signaling and NO production in
wild type aortic explants and cultured human endothelial
cells. Whole body disruption of TLR4 signaling prevents
atherosclerosis in proatherogenic genetic mouse models [57,
58]. Interestingly, in hematopoetic cell TLR4 KO/whole
body LDLR KO agouti mice, only females fed normal chowGastroenterology Research and Practice 7
plus cholesterol diet exhibited less ATM, inﬂammation, and
atheroscleroticlesionsizethanTLR4wild-typecontrols[56].
Inthesestudies,metabolicandatherogenicsequelaewerethe
same in hematopoetic cell TLR4 KO versus wild type females
fed three diﬀerent high-fat diet plus cholesterol formulae.
The authors state that no signiﬁcant phenotypic diﬀerences
were observed between the male genotypes. Direct action of
TLR4 signaling in vascular inﬂammation and atherosclerosis
in vivo is unclear as the phenotypes described above could
be mediated by TLR4 indirectly via reduced inﬂammation
elsewhere (e.g., adipose tissue).
1.9.4. Sex-Speciﬁc Dimorphism. Numerous observations in
the literature reveal sexual dimorphism in the regulation
of TLR4 and TLR4 signaling. Sex hormones diﬀerentially
regulate TLR4 localization, gene expression, and sensitiv-
ity, described above. Males and females exhibit dramatic
diﬀerences in their immune responses and susceptibility
to sepsis [118]. Innate immunity modulation and insulin
resistance are observed in pregnancy during which estrogen
and progesterone levels are dramatically elevated [119–121].
Two of the TLR4 knockout mouse studies described above
report TLR4-dependent phenotypic eﬀects in females only
[26, 56]. Sex diﬀerences in acute lipid infusion-induced
insulin resistance have been reported in both human [122]
and rat [123] studies where only males become insulin
resistant during lipid infusion. Future studies should provide
more clarity about the mechanisms by which TLR4 signaling
is modulated by sex hormones.
2. Conclusion
TLR4 activation promotes insulin resistance. Given the
wide-spread expression pattern of TLR4 in tissues and cell
types that modulate energy homeostasis and insulin action
(Figure 2), the direct, cell type-speciﬁc relationship between
TLR4 activation and insulin resistance is unclear. TLR4 plays
an important insulin-desensitizing role in myeloid-derived
cells and future studies of nonmyeloid, cell type-speciﬁc
transgenic and knockout models are of great interest. Our
increasing understanding of TLR4 and insulin resistance will
facilitate the design of novel therapeutic approaches that can
derail the negative metabolic eﬀects of TLR4 activation from
the important functions of innate immunity.
Acknowledgment
This paper was supported in part by NIH Grant DK075479
(to Jane J. Kim).
References
[1] C. de Luca and J. M. Olefsky, “Inﬂammation and insulin
resistance,” FEBS Letters, vol. 582, no. 1, pp. 97–105, 2008.
[2] S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr.,
and C. Lenfant, “Deﬁnition of metabolic syndrome: report
of the National Heart, Lung, and Blood Institute/American
Heart Association conference on scientiﬁc issues related to
deﬁnition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[3] J. M. Olefsky and C. K. Glass, “Macrophages, inﬂammation,
and insulin resistance,” Annual Review of Physiology, vol. 72,
pp. 219–246, 2010.
[4] P. K. Shah, “Innate immune pathway links obesity to insulin
resistance,” Circulation Research, vol. 100, no. 11, pp. 1531–
1533, 2007.
[5] G. S. Hotamisligil and E. Erbay, “Nutrient sensing and
inﬂammation in metabolic diseases,” Nature Reviews
Immunology, vol. 8, no. 12, pp. 923–934, 2008.
[6] S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity:
modulation by nutrients and inﬂammation,” Journal of
Clinical Investigation, vol. 118, no. 9, pp. 2992–3002, 2008.
[ 7 ]J .M .E h r c h e n ,C .S u n d e r k ¨ otter, D. Foell, T. Vogl, and
J. Roth, “The endogenous Toll-like receptor 4 agonist
S100A8/S100A9 (calprotectin) as innate ampliﬁer of infec-
tion, autoimmunity, and cancer,” Journal of Leukocyte Biol-
ogy, vol. 86, no. 3, pp. 557–566, 2009.
[8] M.E.Bianchi,“HMGB1lovescompany,”Journal of Leukocyte
Biology, vol. 86, no. 3, pp. 573–576, 2009.
[ 9 ] S .P .G o n d o k a ry o n o ,H .U s h i o ,F .N i y o n s a b ae ta l . ,“T h ee x t ra
domain A of ﬁbronectin stimulates murine mast cells via
Toll-like receptor 4,” Journal of Leukocyte Biology, vol. 82, no.
3, pp. 657–665, 2007.
[10] Y. I. Miller, et al., “Toll-like receptor-4 and lipoprotein
accumulation in macrophages,” Trends in Cardiovascular
Medicine, vol. 19, no. 7, pp. 227–232, 2009.
[11] P. Mandal, P.-H. Park, M. R. McMullen, B. T. Pratt, and L.
E. Nagy, “The anti-inﬂammatory eﬀects of adiponectin are
mediated via a heme oxygenase-1-dependent pathway in rat
kupﬀercells,”Hepatology,vol.51,no.4,pp.1420–1429,2010.
[12] H. Huang, P.-H. Park, M. R. McMullen, and L. E.
Nagy, “Mechanisms for the anti-inﬂammatory eﬀects of
adiponectininmacrophages,”JournalofGastroenterologyand
Hepatology, vol. 23, supplement 1, pp. S50–S53, 2008.
[13] N. Kamio, S. Akifusa, N. Yamaguchi, K. Nonaka, and
Y. Yamashita, “Anti-inﬂammatory activity of a globular
adiponectin function on RAW 264 cells stimulated by
lipopolysaccharide from Aggregatibacter actinomycetem-
comitans,” FEMS Immunology and Medical Microbiology, vol.
56, no. 3, pp. 241–247, 2009.
[14] M. Neumeier, J. Weigert, A. Sch¨ aﬄer et al., “Diﬀerent eﬀects
of adiponectin isoforms in human monocytic cells,” Journal
of Leukocyte Biology, vol. 79, no. 4, pp. 803–808, 2006.
[15] N. Yamaguchi, J. G. M. Argueta, Y. Masuhiro et al.,
“Adiponectin inhibits Toll-like receptor family-induced sig-
naling,” FEBS Letters, vol. 579, no. 30, pp. 6821–6826, 2005.
[ 1 6 ]D .S a g ,D .C a r l i n g ,R .D .S t o u t ,a n dJ .S u t t l e s ,“ A d e n o -
sine 5’-monophosphate-activated protein kinase promotes
macrophage polarization to an anti-inﬂammatory functional
phenotype,” Journal of Immunology, vol. 181, no. 12, pp.
8633–8641, 2008.
[17] C. K. Glass and S. Ogawa, “Combinatorial roles of nuclear
receptors in inﬂammation and immunity,” Nature Reviews
Immunology, vol. 6, no. 1, pp. 44–55, 2006.
[18] M. R. Dasu, S. Park, S. Devaraj, and I. Jialal, “Pioglitazone
inhibits toll-like receptor expression and activity in human
monocytes and db/db mice,” Endocrinology, vol. 150, no. 8,
pp. 3457–3464, 2009.
[19] C. M. Reynolds, E. Draper, B. Keogh et al., “A
conjugated linoleic acid-enriched beef diet attenuates
lipopolysaccharide-induced inﬂammation in mice in part
through PPARγ-mediated suppression of toll-like receptor
4,” Journal of Nutrition, vol. 139, no. 12, pp. 2351–2357,
2009.8 Gastroenterology Research and Practice
[20] B. M. Necela, W. Su, and E. A. Thompson, “Toll-like recep-
tor 4 mediates cross-talk between peroxisome proliferator-
activated receptor γ and nuclear factor-κB in macrophages,”
Immunology, vol. 125, no. 3, pp. 344–358, 2008.
[21] L. A. Jones, J.-P. Anthony, F. L. Henriquez et al., “Toll-like
receptor-4-mediated macrophage activation is diﬀerentially
regulated by progesterone via the glucocorticoid and proges-
terone receptors,” Immunology, vol. 125, no. 1, pp. 59–69,
2008.
[ 2 2 ]L .M i l l e r ,E .W .A l l e y ,W .J .M u r p h y ,S .W .R u s s e l l ,a n dJ .S .
Hunt, “Progesterone inhibits inducible nitric oxide synthase
gene expression and nitric oxide production in murine
macrophages,” Journal of Leukocyte Biology,v o l .5 9 ,n o .3 ,p p .
442–450, 1996.
[23] J. A. Rettew, Y. M. Huet, and I. Marriott, “Estrogens augment
cell surface TLR4 expression on murine macrophages and
regulate sepsis susceptibility in vivo,” Endocrinology, vol. 150,
no. 8, pp. 3877–3884, 2009.
[24] J. A. Rettew, Y. M. Huet-Hudson, and I. Marriott, “Testos-
terone reduces macrophage expression in the mouse of
toll-like receptor 4, a trigger for inﬂammation and innate
immunity,” Biology of Reproduction, vol. 78, no. 3, pp. 432–
437, 2008.
[25] J. Y. Lee, K. H. Sohn, S. H. Rhee, and D. Hwang, “Saturated
fatty acids, but not unsaturated fatty acids, induce the
expression of cyclooxygenase-2 mediated through Toll-like
receptor 4,” Journal of Biological Chemistry, vol. 276, no. 20,
pp. 16683–16689, 2001.
[26] H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J.
S. Flier, “TLR4 links innate immunity and fatty acid-induced
insulin resistance,” Journal of Clinical Investigation, vol. 116,
no. 11, pp. 3015–3025, 2006.
[27] J. Y. Lee, A. Plakidas, W. H. Lee et al., “Diﬀerential
modulation of Toll-like receptors by fatty acids: preferential
inhibition by n-3 polyunsaturated fatty acids,” Journal of
Lipid Research, vol. 44, no. 3, pp. 479–486, 2003.
[ 2 8 ]S .W .W o n g ,M . - J .K w o n ,A .M .K .C h o i ,H . - P .K i m ,K .
Nakahira, and D. H. Hwang, “Fatty acids modulate toll-
like receptor 4 activation through regulation of receptor
dimerization and recruitment into lipid rafts in a reactive
oxygen species-dependent manner,” Journal of Biological
Chemistry, vol. 284, no. 40, pp. 27384–27392, 2009.
[29] J. M. Brown, S. Chung, J. K. Sawyer et al., “Inhibition
of stearoyl-coenzyme A desaturase 1 dissociates insulin
resistance and obesity from atherosclerosis,” Circulation, vol.
118, no. 14, pp. 1467–1475, 2008.
[30] M. L. E. MacDonald, M. Van Eck, R. B. Hildebrand et al.,
“Despite antiatherogenic metabolic characteristics, SCD1-
deﬁcient mice have increased inﬂammation and atheroscle-
rosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
29, no. 3, pp. 341–347, 2009.
[31] J.M.Brown,S.Chung,J.K.Sawyeretal.,“Combinedtherapy
of dietary ﬁsh oil and stearoyl-CoA desaturase 1 inhibition
prevents the metabolic syndrome and atherosclerosis,” Arte-
riosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 1,
pp. 24–30, 2010.
[32] R. S. Chapkin, N. Wang, Y.-Y. Fan, J. R. Lupton, and I. A.
Prior, “Docosahexaenoic acid alters the size and distribution
of cell surface microdomains,” Biochimica et Biophysica Acta,
vol. 1778, no. 2, pp. 466–471, 2008.
[33] Q. Li, M. Wang, L. Tan et al., “Docosahexaenoic acid changes
lipid composition and interleukin-2 receptor signaling in
membrane rafts,” Journal of Lipid Research, vol. 46, no. 9, pp.
1904–1913, 2005.
[34] T. M. Stulnig, J. Huber, N. Leitinger et al., “Polyunsaturated
eicosapentaenoic acid displaces proteins from membrane
rafts by altering raft lipid composition,” Journal of Biological
Chemistry, vol. 276, no. 40, pp. 37335–37340, 2001.
[35] M.B.Fessler,L.L.Rudel,andJ.M.Brown,“Toll-likereceptor
signalinglinksdietaryfattyacidstothemetabolicsyndrome,”
Current Opinion in Lipidology, vol. 20, no. 5, pp. 379–385,
2009.
[ 3 6 ]B .S .P a r k ,D .H .S o n g ,H .M .K i m ,B . - S .C h o i ,H .L e e ,
and J.-O. Lee, “The structural basis of lipopolysaccharide
recognition by the TLR4-MD-2 complex,” Nature, vol. 458,
no. 7242, pp. 1191–1195, 2009.
[37] C. Erridge and N. J. Samani, “Saturated fatty acids do not
directlystimulatetoll-likereceptorsignaling,”Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 29, no. 11, pp. 1944–
1949, 2009.
[38] B. Gao and M.-F. Tsan, “Recombinant human heat shock
protein 60 does not induce the release of tumor necrosis
factor α from murine macrophages,” Journal of Biological
Chemistry, vol. 278, no. 25, pp. 22523–22529, 2003.
[39] K. E. Taylor, J. C. Giddings, and C. W. Van Den Berg, “C-
reactive protein-induced in vitro endothelial cell activation
is an artefact caused by azide and lipopolysaccharide,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no.
6, pp. 1225–1230, 2005.
[40] J. Cohen, “The detection and interpretation of endotox-
aemia,” Intensive Care Medicine, Supplement, vol. 26, supple-
ment 1, pp. S51–S56, 2000.
[41] P. Brun, I. Castagliuolo, V. Di Leo et al., “Increased intestinal
permeabilityinobesemice:newevidenceinthepathogenesis
of nonalcoholic steatohepatitis,” American Journal of Physiol-
ogy, vol. 292, no. 2, pp. G518–G525, 2007.
[42] P. D. Cani and N. M. Delzenne, “The role of the gut
microbiota in energy metabolism and metabolic disease,”
Current Pharmaceutical Design, vol. 15, no. 13, pp. 1546–
1558, 2009.
[43] C. Erridge, T. Attina, C. M. Spickett, and D. J. Webb, “A high-
fat meal induces low-grade endotoxemia: evidence of a novel
mechanismofpostprandialinﬂammation,”AmericanJournal
of Clinical Nutrition, vol. 86, no. 5, pp. 1286–1292, 2007.
[44] A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S. C.
Bischoﬀ, and I. Bergheim, “Toll-like receptor 4 is involved
in the development of fructose-induced hepatic steatosis in
mice,” Hepatology, vol. 50, no. 4, pp. 1094–1104, 2009.
[45] S. Ghoshal, J. Witta, J. Zhong, W. de Villiers, and E.
Eckhardt, “Chylomicrons promote intestinal absorption of
lipopolysaccharides,” Journal of Lipid Research, vol. 50, no. 1,
pp. 90–97, 2009.
[46] M. D. Neal, C. Leaphart, R. Levy et al., “Enterocyte TLR4
mediates phagocytosis and translocation of bacteria across
the intestinal barrier,” Journal of Immunology, vol. 176, no.
5, pp. 3070–3079, 2006.
[47] S. J. Creely, P. G. McTernan, C. M. Kusminski et al.,
“Lipopolysaccharide activates an innate immune system
response in human adipose tissue in obesity and type 2
diabetes,” American Journal of Physiology, vol. 292, no. 3, pp.
E740–E747, 2007.
[48] M. R. Dasu, S. Devaraj, S. Park, and I. Jialal, “Increased Toll-
Like Receptor (TLR) activation and TLR ligands in recently
diagnosedtype2diabeticsubjects,”DiabetesCare,vol.33,no.
4, pp. 861–868, 2010.
[49] P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotox-
emia initiates obesity and insulin resistance,” Diabetes, vol.
56, no. 7, pp. 1761–1772, 2007.Gastroenterology Research and Practice 9
[50] F. B¨ ackhed, J. K. Manchester, C. F. Semenkovich, and
J. I. Gordon, “Mechanisms underlying the resistance to
diet-induced obesity in germ-free mice,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 3, pp. 979–984, 2007.
[51] P. D. Cani, R. Bibiloni, C. Knauf et al., “Changes in gut
microbiota control metabolic endotoxemia-induced inﬂam-
mation in high-fat diet-induced obesity and diabetes in
mice,” Diabetes, vol. 57, no. 6, pp. 1470–1481, 2008.
[52] M. Membrez, F. Blancher, M. Jaquet et al., “Gut microbiota
modulation with norﬂoxacin and ampicillin enhances glu-
cose tolerance in mice,” FASEB Journal,v o l .2 2 ,n o .7 ,p p .
2416–2426, 2008.
[53] F. Kim, M. Pham, I. Luttrell et al., “Toll-like receptor-4
mediates vascular inﬂammation and insulin resistance in
diet-induced obesity,” Circulation Research, vol. 100, no. 11,
pp. 1589–1596, 2007.
[54] M. Saberi, N.-B. Woods, C. de Luca et al., “Hematopoietic
cell-speciﬁc deletion of toll-like receptor 4 ameliorates
hepatic and adipose tissue insulin resistance in high-fat-fed
mice,” Cell Metabolism, vol. 10, no. 5, pp. 419–429, 2009.
[55] J. E. Davis, N. K. Gabler, J. Walker-Daniels, and M. E. Spur-
lock, “Tlr-4 deﬁciency selectively protects against obesity
induced by diets high in saturated fat,” Obesity, vol. 16, no.
6, pp. 1248–1255, 2008.
[ 5 6 ]K .R .C o e n e n ,M .L .G r u e n ,R .S .L e e - Y o u n g ,M .J .P u g l i s i ,
D. H. Wasserman, and A. H. Hasty, “Impact of macrophage
toll-likereceptor4deﬁciencyonmacrophageinﬁltrationinto
adipose tissue and the artery wall in mice,” Diabetologia, vol.
52, no. 2, pp. 318–328, 2009.
[57] K. S. Michelsen, M. H. Wong, P. K. Shah et al., “Lack of toll-
like receptor 4 or myeloid diﬀerentiation factor 88 reduces
atherosclerosis and alters plaque phenotype in mice deﬁcient
in apolipoprotein E,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 101, no. 29, pp.
10679–10684, 2004.
[58] H. Bj¨ orkbacka, V. V. Kunjathoor, K. J. Moore et al., “Reduced
atherosclerosis in MyD88-null mice links elevated serum
cholesterol levels to activation of innate immunity signaling
pathways,”Nature Medicine,vol.10,no.4,pp.416–421,2004.
[59] R. Roncon-Albuquerque Jr., M. Moreira-Rodrigues, B. Faria
et al., “Attenuation of the cardiovascular and metabolic
complications of obesity in CD14 knockout mice,” Life
Sciences, vol. 83, no. 13-14, pp. 502–510, 2008.
[60] R. A. Bagarolli, M. J. A. Saad, and S. T. O. Saad, “Toll-
like receptor 4 and inducible nitric oxide synthase gene
polymorphisms are associated with type 2 diabetes,” Journal
of Diabetes and Its Complications, vol. 24, no. 3, pp. 192–198,
2010.
[61] B. Ferwerda, M. B. B. McCall, K. Verheijen et al., “Functional
consequences of toll-like receptor 4 polymorphisms,” Molec-
ular Medicine, vol. 14, no. 5-6, pp. 346–352, 2008.
[62] A. P. Steinhardt, F. Aranguren, M. L. Tellechea et al., “A
functional nonsynonymous toll-like receptor 4 gene poly-
morphismisassociatedwithmetabolicsyndrome,surrogates
of insulin resistance, and syndromes of lipid accumulation,”
Metabolism, vol. 59, no. 5, pp. 711–717, 2010.
[63] R. Coppari, M. Ichinose, C. E. Lee et al., “The hypotha-
lamic arcuate nucleus: a key site for mediating leptin’s
eﬀects on glucose homeostasis and locomotor activity,” Cell
Metabolism, vol. 1, no. 1, pp. 63–72, 2005.
[64] A. Pocai, K. Morgan, C. Buettner, R. Gutierrez-Juarez, S.
Obici, and L. Rossetti, “Central leptin acutely reverses diet-
induced hepatic insulin resistance,” Diabetes, vol. 54, no. 11,
pp. 3182–3189, 2005.
[65] S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as
an endocrine organ,” Molecular and Cellular Endocrinology,
vol. 316, no. 2, pp. 129–139, 2009.
[66] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.
L. Leibel, and A. W. Ferrante Jr., “Obesity is associated
with macrophage accumulation in adipose tissue,” Journal of
Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.
[67] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inﬂammation in
fat plays a crucial role in the development of obesity-related
insulin resistance,” Journal of Clinical Investigation, vol. 112,
no. 12, pp. 1821–1830, 2003.
[68] P. J. Bilan, V. Samokhvalov, A. Koshkina, J. D. Schertzer, M.
C. Samaan, and A. Klip, “Direct and macrophage-mediated
actions of fatty acids causing insulin resistance in muscle
cells,” Archives of Physiology and Biochemistry, vol. 115, no.
4, pp. 176–190, 2009.
[ 6 9 ]D .P a t s o u r i s ,P . - P .L i ,D .T h a p a r ,J .C h a p m a n ,J .M .O l e f s k y ,
and J. G. Neels, “Ablation of CD11c-positive cells normalizes
insulin sensitivity in obese insulin resistant animals,” Cell
Metabolism, vol. 8, no. 4, pp. 301–309, 2008.
[70] S. Cinti, G. Mitchell, G. Barbatelli et al., “Adipocyte death
deﬁnes macrophage localization and function in adipose
tissue of obese mice and humans,” Journal of Lipid Research,
vol. 46, no. 11, pp. 2347–2355, 2005.
[71] M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of
obesity- and diet-induced insulin resistance with salicylates
or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535,
pp. 1673–1677, 2001.
[72] M. C. Arkan, A. L. Hevener, F. R. Greten et al., “IKK-β links
inﬂammation to obesity-induced insulin resistance,” Nature
Medicine, vol. 11, no. 2, pp. 191–198, 2005.
[73] G. Solinas, C. Vilcu, J. G. Neels et al., “JNK1 in hematopoi-
etically derived cells contributes to diet-induced inﬂamma-
tion and insulin resistance without aﬀecting obesity,” Cell
Metabolism, vol. 6, no. 5, pp. 386–397, 2007.
[74] J. K. Kim, J. J. Fillmore, M. J. Sunshine et al., “PKC-
θ knockout mice are protected from fat-induced insulin
resistance,” Journal of Clinical Investigation, vol. 114, no. 6,
pp. 823–827, 2004.
[75] H.-M. Zhang, L.-L. Chen, L. Wang et al., “Macrophage
inﬁltrateswithhighlevelsofToll-likereceptor4expressionin
whiteadiposetissuesofmaleChinese,”Nutrition,Metabolism
and Cardiovascular Diseases, vol. 19, no. 10, pp. 736–743,
2009.
[76] M. T. A. Nguyen, S. Favelyukis, A.-K. Nguyen et al.,
“A subpopulation of macrophages inﬁltrates hypertrophic
adipose tissue and is activated by free fatty acids via Toll-like
receptors 2 and 4 and JNK-dependent pathways,” Journal of
BiologicalChemistry,vol.282,no.48,pp.35279–35292,2007.
[77] S. B` es-Houtmann, R. Roche, L. Hoareau et al., “Presence
of functional TLR2 and TLR4 on human adipocytes,”
Histochemistry and Cell Biology, vol. 127, no. 2, pp. 131–137,
2007.
[ 7 8 ] M .J .S o n g ,K .H .K i m ,J .M .Y o o n ,a n dJ .B .K i m ,“ A c t i v a t i o n
of Toll-like receptor 4 is associated with insulin resistance in
adipocytes,” Biochemical and Biophysical Research Communi-
cations, vol. 346, no. 3, pp. 739–745, 2006.
[79] O. I. Vitseva, K. Tanriverdi, T. T. Tchkonia et al., “Inducible
Toll-like receptor and NF-κB regulatory pathway expression
inhumanadiposetissue,”Obesity,vol.16,no.5,pp.932–937,
2008.
[80] K. Hoshino, O. Takeuchi, T. Kawai et al., “Cutting edge: Toll-
like receptor 4 (TLR4)-deﬁcient mice are hyporesponsive
to lipopolysaccharide evidence for TLR4 as the Lps gene10 Gastroenterology Research and Practice
product,” Journal of Immunology, vol. 162, no. 7, pp. 3749–
3752, 1999.
[81] A. Poltorak, X. He, I. Smirnova et al., “Defective LPS
signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in
Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998.
[82] C. R. H. Raetz, “Biochemistry of endotoxins,” Annual Review
of Biochemistry, vol. 59, pp. 129–170, 1990.
[83] Y. Lin, H. Lee, A. H. Berg, M. P. Lisanti, L. Shapiro, and P. E.
Scherer, “The lipopolysaccharide-activated Toll-like receptor
(TLR)-4 induces synthesis of the closely related receptor
TLR-2 in adipocytes,” Journal of Biological Chemistry, vol.
275, no. 32, pp. 24255–24263, 2000.
[84] J.Y.LeeandD.H.Hwang,“Themodulationofinﬂammatory
gene expression by lipids: mediation through Toll-like recep-
tors,” Molecules and Cells, vol. 21, no. 2, pp. 174–185, 2006.
[85] L. H. Storlien, E. W. Kraegen, and D. J. Chisholm, “Fish oil
prevents insulin resistance induced by high-fat feeding in
rats,” Science, vol. 237, no. 4817, pp. 885–888, 1987.
[86] T. Suganami, T. Mieda, M. Itoh, Y. Shimoda, Y. Kamei,
and Y. Ogawa, “Attenuation of obesity-induced adipose
tissue inﬂammation in C3H/HeJ mice carrying a Toll-like
receptor 4 mutation,” Biochemical and Biophysical Research
Communications, vol. 354, no. 1, pp. 45–49, 2007.
[87] D. M. L. Tsukumo, M. A. Carvalho-Filho, J. B. C. Carvalheira
et al., “Loss-of-function mutation in Toll-like receptor 4 pre-
vents diet-induced obesity and insulin resistance,” Diabetes,
vol. 56, no. 8, pp. 1986–1998, 2007.
[88] M. Poggi, D. Bastelica, P. Gual et al., “C3H/HeJ mice carrying
a Toll-like receptor 4 mutation are protected against the
development of insulin resistance in white adipose tissue in
response to a high-fat diet,” Diabetologia,v o l .5 0 ,n o .6 ,p p .
1267–1276, 2007.
[89] T. Suganami, K. Tanimoto-Koyama, J. Nishida et al., “Role
of the Toll-like receptor 4/NF-κB pathway in saturated
fatty acid-induced inﬂammatory changes in the interac-
tion between adipocytes and macrophages,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 84–91,
2007.
[90] V. D. F. De Mello, M. Kolehmainen, L. Pulkkinen et al.,
“Downregulation of genes involved in NFκB activation in
peripheral blood mononuclear cells after weight loss is
associated with the improvement of insulin sensitivity in
individuals with the metabolic syndrome: the GENOBIN
study,” Diabetologia, vol. 51, no. 11, pp. 2060–2067, 2008.
[91] L. Bouwens, M. Baekeland, R. De Zanger, and E. Wisse,
“Quantitation, tissue distribution and proliferation kinetics
of Kupﬀer cells in normal rat liver,” Hepatology, vol. 6, no. 4,
pp. 718–722, 1986.
[92] K. Miura, et al., “Role of Toll-like receptors and their
downstream molecules in the development of non-alcoholic
fatty liver disease,” Gastroenterology Research and Practice.I n
press.
[93] G. Baﬀy, “Kupﬀer cells in non-alcoholic fatty liver disease:
the emerging view,” Journal of Hepatology,v o l .5 1 ,n o .1 ,p p .
212–223, 2009.
[ 9 4 ]L .A .V i d e l a ,G .T a p i a ,R .R o d r i g oe ta l . ,“ L i v e rN F - κBa n d
AP-1 DNA binding in obese patients,” Obesity,v o l .1 7 ,n o .5 ,
pp. 973–979, 2009.
[95] C. F. Raetzsch, N. L. Brooks, J. M. Alderman et al.,
“Lipopolysaccharide inhibition of glucose production
through the Toll-like receptor-4, myeloid diﬀerentiation
factor 88, and nuclear factor κBp a t h w a y , ”Hepatology, vol.
50, no. 2, pp. 592–600, 2009.
[96] R. A. DeFronzo, R. Gunnarsson, and O. Bjorkman, “Eﬀects
of insulin on peripheral and splanchnic glucose metabolism
in noninsulin-dependent (type II) diabetes mellitus,” Journal
of Clinical Investigation, vol. 76, no. 1, pp. 149–155, 1985.
[97] A. D. Baron, G. Brechtel, P. Wallace, and S. V. Edelman,
“Rates and tissue sites of non-insulin- and insulin-mediated
glucose uptake in humans,” American Journal of Physiology,
vol. 255, no. 6, part 1, pp. E769–E774, 1988.
[98] O. G. Kolterman, J. Insel, M. Saekow, and J. M. Olef-
sky, “Mechanisms of insulin resistance in human obesity.
Evidence for receptor and postreceptor defects,” Journal of
Clinical Investigation, vol. 65, no. 6, pp. 1272–1284, 1980.
[99] G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F.
White, and B. M. Spiegelman, “IRS-1-mediated inhibition
of insulin receptor tyrosine kinase activity in TNF-α-a n d
obesity-induced insulin resistance,” Science, vol. 271, no.
5249, pp. 665–668, 1996.
[100] M. I. Frisard, R. P. McMillan, J. Marchand et al., “Toll-like
receptor 4 modulates skeletal muscle substrate metabolism,”
American Journal of Physiology, vol. 298, no. 5, pp. E988–
E998, 2010.
[101] Y. Wei, K. Chen, A. T. Whaley-Connell, C. S. Stump, J. A.
Ibdah, and J. R. Sowers, “Skeletal muscle insulin resistance:
role of inﬂammatory cytokines and reactive oxygen species,”
American Journal of Physiology, vol. 294, no. 3, pp. R673–
R680, 2008.
[102] J.H.Boyd,M.Divangahi,L.Yahiaoui,D.Gvozdic,S.Qureshi,
and B. J. Petrof, “Toll-like receptors diﬀerentially regulate
CC and CXC chemokines in skeletal muscle via NF-κBa n d
calcineurin,” Infection and Immunity, vol. 74, no. 12, pp.
6829–6838, 2006.
[103] S. M. Reyna, S. Ghosh, P. Tantiwong et al., “Elevated Toll-like
receptor 4 expression and signaling in muscle from insulin-
resistant subjects,” Diabetes, vol. 57, no. 10, pp. 2595–2602,
2008.
[104] J. J. Senn, “Toll-like receptor-2 is essential for the develop-
ment of palmitate-induced insulin resistance in myotubes,”
Journal of Biological Chemistry, vol. 281, no. 37, pp. 26865–
26875, 2006.
[105] D. A. Sandoval, S. Obici, and R. J. Seeley, “Targeting the CNS
to treat type 2 diabetes,” Nature Reviews Drug Discovery, vol.
8, no. 5, pp. 386–398, 2009.
[106] S.-H. Chiang, M. Bazuine, C. N. Lumeng et al., “The protein
kinaseIKKεregulatesenergybalanceinobesemice,”Cell,vol.
138, no. 5, pp. 961–975, 2009.
[107] C. T. De Souza, E. P. Araujo, S. Bordin et al., “Consumption
of a fat-rich diet activates a proinﬂammatory response and
induces insulin resistance in the hypothalamus,” Endocrinol-
ogy, vol. 146, no. 10, pp. 4192–4199, 2005.
[108] A. Kleinridders, D. Schenten, A. C. K¨ onner et al., “MyD88
signaling in the CNS is required for development of fatty
acid-induced leptin resistance and diet-induced obesity,” Cell
Metabolism, vol. 10, no. 4, pp. 249–259, 2009.
[109] J.C.Moraes,A.Coope,J.Morarietal.,“High-fatdietinduces
apoptosis of hypothalamic neurons,” PLoS ONE,v o l .4 ,n o .4 ,
article e5045, 2009.
[110] L. Wen, J. Peng, Z. Li, and F. S. Wong, “The eﬀect of innate
immunity on autoimmune diabetes and the expression of
Toll-like receptors on pancreatic islets,” Journal of Immunol-
ogy, vol. 172, no. 5, pp. 3173–3180, 2004.
[111] A. Goldberg, M. Parolini, B. Y. Chin et al., “Toll-like receptor
4 suppression leads to islet allograft survival,” FASEB Journal,
vol. 21, no. 11, pp. 2840–2848, 2007.Gastroenterology Research and Practice 11
[112] H. S. Kim, M. S. Han, K. W. Chung et al., “Toll-like receptor
2s e n s e sβ-cell death and contributes to the initiation of
autoimmunediabetes,”Immunity,vol.27,no.2,pp.321–333,
2007.
[113] L. Wen, R. E. Ley, P. Y. Volchkov et al., “Innate immunity and
intestinal microbiota in the development of type 1 diabetes,”
Nature, vol. 455, no. 7216, pp. 1109–1113, 2008.
[114] F. S. Wong, C. Hu, L. Zhang et al., “The role of Toll-
like receptors 3 and 9 in the development of autoimmune
diabetes in NOD mice,” Annals of the New York Academy of
Sciences, vol. 1150, pp. 146–148, 2008.
[115] F. T. Schulthess, F. Paroni, N. S. Sauter et al., “CXCL10
impairs β cell function and viability in diabetes through
TLR4 signaling,” Cell Metabolism, vol. 9, no. 2, pp. 125–139,
2009.
[116] M. B¨ oni-Schnetzler, S. Boller, S. Debray et al., “Free fatty
acids induce a proinﬂammatory response in islets via the
abundantly expressed interleukin-1 receptor I,” Endocrinol-
ogy, vol. 150, no. 12, pp. 5218–5229, 2009.
[117] X. Li, J. C. Tupper, D. D. Bannerman, R. K. Winn, C.
J. Rhodes, and J. M. Harlan, “Phosphoinositide 3 kinase
mediates Toll-like receptor 4-induced activation of NF-κBi n
endothelial cells,” Infection and Immunity,v o l .7 1 ,n o .8 ,p p .
4414–4420, 2003.
[118] I. Marriott and Y. M. Huet-Hudson, “Sexual dimorphism in
innate immune responses to infectious organisms,” Immuno-
logic Research, vol. 34, no. 3, pp. 177–192, 2006.
[119] M.-P. Piccinni, E. Maggi, and S. Romagnani, “Role of
hormone-controlled T-cell cytokines in the maintenance of
pregnancy,” Biochemical Society Transactions,v o l .2 8 ,n o .2 ,
pp. 212–215, 2000.
[120] R. Raghupathy, “Th1-type immunity is incompatible with
successful pregnancy,” Immunology Today, vol. 18, no. 10, pp.
478–482, 1997.
[121] T. G. Wegmann, H. Lin, L. Guilbert, and T. R. Mosmann,
“Bidirectional cytokine interactions in the maternal-fetal
relationship: is successful pregnancy a TH2 phenomenon?”
Immunology Today, vol. 14, no. 7, pp. 353–356, 1993.
[122] J. P. Frias, G. B. Macaraeg, J. Ofrecio, J. G. Yu, J. M. Olefsky,
and Y. T. Kruszynska, “Decreased susceptibility to fatty
acid-induced peripheral tissue insulin resistance in women,”
Diabetes, vol. 50, no. 6, pp. 1344–1350, 2001.
[123] A. Hevener, D. Reichart, A. Janez, and J. Olefsky, “Female
rats do not exhibit free fatty acid-induced insulin resistance,”
Diabetes, vol. 51, no. 6, pp. 1907–1912, 2002.